Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $47 to $45.
Read original at benzingaStocks · News reference
Dyne Therapeutics Stock Tumbles After Hours: Here's Why
Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 22, 2026, 5:52 AM
- Checked
- Jul 22, 2026, 5:52 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35
Read original at benzingaDyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate
Read original at benzinga8-K filing — Dyne Therapeutics, Inc. (DYN)
Filed: 2026-07-29 AccNo: 0001193125-26-323940 Size: 332 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar'Jefferies Targets €1 Billion for Private Credit Secondaries Fund' - Bloomberg
https://www.bloomberg.com/news/articles/2026-08-19/jefferies-targets-1-billion-for-private-credit-secondaries-fund
Read original at benzingaBerkshire Hathaway 13F Preview: What Stock Moves Did Buffett Successor Greg Abel Make?
Berkshire Hathaway will report their Q2 holdings via a 13F filing on Friday. Here's a look at how the portfolio could change.
Read original at benzinga